Shire Plc American Depositary Shares (SHPG) 168.15 $SHPG
Can Allergan Remain Independent of Valeant?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu May 08, 5:30PM CDT
Thanks to the now-public interest of Valeant in making Allergan its own, not to mention the vocal and financial support of Pershing Square and Bill Ackman, the status quo is gone for good at Allergan. Good first...
Corcept Plunges on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:35PM CDT
Shares of Corcept Therapeutics Inc. (CORT) were down 50.5% after the company announced that it will discontinue the study on Korlym (study 14) for the treatment of psychotic depression.
ArQule Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:58PM CDT
ArQule (ARQL) reported a loss of 11 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 12 cents per share.
Actavis, Michael Kors Among World Stocks Near Buy Points
at Investor's Business Daily - Tue May 06, 5:50PM CDT
Leading international stocks have proved highly resilient amid the market's correction. Two of IBD's current Top World Stocks, Ireland's Shire (SHPG) and Singapore-based Avago Technologies (AVGO), recently cleared buy points and moved to new highs....
Akorn Q1 EPS Beats, Raises Full-Year Profit Outlook
at Investor's Business Daily - Tue May 06, 11:11AM CDT
Specialty drugmaker Akorn (AKRX) on Tuesday reported first-quarter EPS above views, but revenue was light. The company also raised its full-year profit outlook. Lake Forest, Ill.-based Akorn said that it earned 16 cents per share in the three months...
Handful Of IBD 50 Stocks Break Out In Heavy Volume
at Investor's Business Daily - Fri May 02, 5:44PM CDT
A handful of IBD 50 stocks broke out of bases in heavy volume last week following mostly positive earnings reports. For the week, the list of leading stocks rose 1.9%, better than the S&P 500's 1.1% gain. AmTrust Financial Services (AFSI) showed the...
Shire Beats on Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:05PM CDT
Shire (SHPG) reported first quarter 2014 earnings (excluding special items and amortization) of $2.36 per American Depositary Share (ADS), up from $1.72 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.22.
Shire to Present Scientific Data at American Psychiatric Association Annual Meeting
M2 - Fri May 02, 10:04AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that seven posters highlighting scientific data and clinical research will be presented at the upcoming American Psychiatric Association (APA) 167th Annual Meeting in New York City, May 3 to May 7, 2014. These data represent Shire's ongoing commitment to clinical research and to understanding the unmet needs of patients.
PharmaPoint Report 2014: Ulcerative Colitis - Current and Future Players
M2 - Fri May 02, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4v75g/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Current and Future Players" report to their offering. PharmaPoint: Ulcerative Colitis - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Ulcerative Colitis Market. The report identifies and analyses the key companies shaping and driving the global Ulcerative Colitis market. The report provides insight into the competitive Ulcerative Colitis landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Ulcerative Colitis - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Ulcerative Colitis sector through market impact analysis, future market scenario and company analysis Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/w4...harmapoint
Transport, Drug Stocks Act Well Despite Market Woes
at Investor's Business Daily - Thu May 01, 5:42PM CDT
Transportation and drug stocks are holding up relatively well during the market's correction, with several in buying range after strong breakouts. Old Dominion Freight Lines (ODFL) cleared a 57.58 base-on-base buy point April 24 in heavy volume. It's...
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...
Stocks Find Footing Near Midday; Kirby Breaks Out
at Investor's Business Daily - Thu May 01, 11:00AM CDT
Stocks were higher near Thursday's halftime after wavering earlier in the session. Boosted by software and solar stocks, the Nasdaq outperformed, rising 0.8%. The S&P 500 rose 0.2%, while the Dow Jones industrial average ticked up a fraction. Volume...
Trade-Ideas: Shire (SHPG) Is Today's Momo Momentum Stock
at The Street - Thu May 01, 8:54AM CDT
Trade-Ideas LLC identified Shire (SHPG) as a momo momentum candidate
Shire Delivers a Strong Start to 2014 and Increases Full Year Guidance
PR Newswire Europe - Thu May 01, 6:03AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ --
Shire Announces Updates from Phase 3 Clinical Program for Lifitegrast in Adults With Dry Eye Disease
PR Newswire Europe - Wed Apr 30, 8:03AM CDT
LEXINGTON, Massachusetts, April 30, 2014 /PRNewswire/ --
Will Allergan Buy Its Way out of a Takeover?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 6:13PM CDT
There has been no shortage of drama relating to Valeant Pharmaceuticals' proposed takeover of Allergan . Valeant's proposed takeover is estimated to generate a potential $2.7 billion in cost savings for the combined company, in part by...
Stocks Modestly Higher; Earnings Lift MGM
at Investor's Business Daily - Tue Apr 29, 10:56AM CDT
Stocks were off their session highs Tuesday, but still modestly higher after a batch of earnings reports and mixed housing and sentiment data. The Nasdaq rose 0.5% and the S&P 500 climbed 0.4%. Both were up as much as 0.7% and 0.5% intraday....
Can Allergan Remain Independent of Valeant?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu May 08, 5:30PM CDT
Thanks to the now-public interest of Valeant in making Allergan its own, not to mention the vocal and financial support of Pershing Square and Bill Ackman, the status quo is gone for good at Allergan. Good first...
Corcept Plunges on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:35PM CDT
Shares of Corcept Therapeutics Inc. (CORT) were down 50.5% after the company announced that it will discontinue the study on Korlym (study 14) for the treatment of psychotic depression.
ArQule Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:58PM CDT
ArQule (ARQL) reported a loss of 11 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 12 cents per share.
Actavis, Michael Kors Among World Stocks Near Buy Points
at Investor's Business Daily - Tue May 06, 5:50PM CDT
Leading international stocks have proved highly resilient amid the market's correction. Two of IBD's current Top World Stocks, Ireland's Shire (SHPG) and Singapore-based Avago Technologies (AVGO), recently cleared buy points and moved to new highs....
Akorn Q1 EPS Beats, Raises Full-Year Profit Outlook
at Investor's Business Daily - Tue May 06, 11:11AM CDT
Specialty drugmaker Akorn (AKRX) on Tuesday reported first-quarter EPS above views, but revenue was light. The company also raised its full-year profit outlook. Lake Forest, Ill.-based Akorn said that it earned 16 cents per share in the three months...
Handful Of IBD 50 Stocks Break Out In Heavy Volume
at Investor's Business Daily - Fri May 02, 5:44PM CDT
A handful of IBD 50 stocks broke out of bases in heavy volume last week following mostly positive earnings reports. For the week, the list of leading stocks rose 1.9%, better than the S&P 500's 1.1% gain. AmTrust Financial Services (AFSI) showed the...
Shire Beats on Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:05PM CDT
Shire (SHPG) reported first quarter 2014 earnings (excluding special items and amortization) of $2.36 per American Depositary Share (ADS), up from $1.72 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.22.
Shire to Present Scientific Data at American Psychiatric Association Annual Meeting
M2 - Fri May 02, 10:04AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that seven posters highlighting scientific data and clinical research will be presented at the upcoming American Psychiatric Association (APA) 167th Annual Meeting in New York City, May 3 to May 7, 2014. These data represent Shire's ongoing commitment to clinical research and to understanding the unmet needs of patients.
PharmaPoint Report 2014: Ulcerative Colitis - Current and Future Players
M2 - Fri May 02, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4v75g/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Current and Future Players" report to their offering. PharmaPoint: Ulcerative Colitis - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Ulcerative Colitis Market. The report identifies and analyses the key companies shaping and driving the global Ulcerative Colitis market. The report provides insight into the competitive Ulcerative Colitis landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Ulcerative Colitis - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Ulcerative Colitis sector through market impact analysis, future market scenario and company analysis Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/w4...harmapoint
Transport, Drug Stocks Act Well Despite Market Woes
at Investor's Business Daily - Thu May 01, 5:42PM CDT
Transportation and drug stocks are holding up relatively well during the market's correction, with several in buying range after strong breakouts. Old Dominion Freight Lines (ODFL) cleared a 57.58 base-on-base buy point April 24 in heavy volume. It's...
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...
Stocks Find Footing Near Midday; Kirby Breaks Out
at Investor's Business Daily - Thu May 01, 11:00AM CDT
Stocks were higher near Thursday's halftime after wavering earlier in the session. Boosted by software and solar stocks, the Nasdaq outperformed, rising 0.8%. The S&P 500 rose 0.2%, while the Dow Jones industrial average ticked up a fraction. Volume...
Trade-Ideas: Shire (SHPG) Is Today's Momo Momentum Stock
at The Street - Thu May 01, 8:54AM CDT
Trade-Ideas LLC identified Shire (SHPG) as a momo momentum candidate
Shire Delivers a Strong Start to 2014 and Increases Full Year Guidance
PR Newswire Europe - Thu May 01, 6:03AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ --
Shire Announces Updates from Phase 3 Clinical Program for Lifitegrast in Adults With Dry Eye Disease
PR Newswire Europe - Wed Apr 30, 8:03AM CDT
LEXINGTON, Massachusetts, April 30, 2014 /PRNewswire/ --
Will Allergan Buy Its Way out of a Takeover?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 6:13PM CDT
There has been no shortage of drama relating to Valeant Pharmaceuticals' proposed takeover of Allergan . Valeant's proposed takeover is estimated to generate a potential $2.7 billion in cost savings for the combined company, in part by...
Stocks Modestly Higher; Earnings Lift MGM
at Investor's Business Daily - Tue Apr 29, 10:56AM CDT
Stocks were off their session highs Tuesday, but still modestly higher after a batch of earnings reports and mixed housing and sentiment data. The Nasdaq rose 0.5% and the S&P 500 climbed 0.4%. Both were up as much as 0.7% and 0.5% intraday....
